Empagliflozin is a newly developed inhibitor of sodium-glucose cotransporter-2 (SGLT2) approved as an antidiabetic medication for patients with type 2 diabetes mellitus. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.